You're viewing a free preview.You're viewing a free preview — a sample of each dataset.
Clinical Trials
Longevity-relevant trials by phase, sponsor, status and indication.
1,136 clinical trials tracked
| Trial | Phase | Status |
|---|---|---|
| Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH) | Phase 2 | Active, not recruiting |
| Cognition, Age, and Rapamycin Effectiveness - Downregulation of the mTOR Pathway (CARPE DIEM) | Phase 1 | Completed |
| The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S): A Randomised Controlled Trial | Not Applicable | Recruiting |
| The Level of Frailty in Individuals Diagnosed With Primary Sarcopenia; Balance, Fall Risk and Impact on Kinesiophobia | — | Completed |
| An Observational, Cross-Sectional Study Evaluating the Impact of Long-Term Supplement Use on Biological Age and Metabolic Health Markers - The BioAge Trial | — | Recruiting |
| Effects of Otago-based Multicomponent Exercise on Sarcopenia in Pre-Frailty Older Adults in Nursing Homes: A Randomized Controlled Trial | Not Applicable | Completed |
| Predicting Biological Age Using Electronic Health Records: An AI-Based Approach | — | Recruiting |
| Evaluation of an ICT-based Platform for Early Detection and Intervention to Prevent Frailty in Older Adults | Not Applicable | Completed |
| A Multicenter, Feasibility Randomized Controlled Study to Evaluate the Applicability and Safety of the Software 'SUPERAGING' for Cognitive Therapy and Musculoskeletal Analysis in Frail or Prefrail Patients | Not Applicable | Recruiting |
| Effect of a Multicomponent Therapeutic Exercise Program in Primary Care on Frailty and Sarcopenia in Older Adults | Not Applicable | Not yet recruiting |
Showing 10 of 1,136 clinical trials
7-day free trial · already have an account?
Peek at other modules
News Feed
Curated longevity industry headlines with AI summaries, updated continuously.
Companies
The longevity company universe by segment, stage, geography and capital raised.
Funding Tracker
Every disclosed longevity round — size, stage and the investors behind it.
People & Movers
Who is joining, leaving and founding across the longevity sector.
Research
Peer-reviewed aging research distilled into investor-relevant takeaways.
Regulatory
FDA, EMA and policy developments that move the longevity market.